Impact of diagnostic delays and short treatment regimens on outcomes of rifampicin-resistant tuberculosis patients in Cameroon KU Leuven
Rifampicin-resistant tuberculosis (RR-TB) remains a major health challenge in low- and middle-income countries despite availability of diagnostic platforms and treatment options. Despite, increasing, increasing use of rapid molecular tests (e.g., Xpert MTB/RIF or Ultra) for detection of RR-TB globally, there is still a major RR-TB diagnostic gap and low treatment success of those started on treatment. Short injectable-containing regimens ...